Reports Q revenue $183.5M, consensus $187.13M. Reports Q2 testing volume grew 17% year-over-year, excluding contributions from the SneakPeek early gender DNA Test. Hereditary cancer test volumes grew 20% year-over-year, the third consecutive quarter of double-digit growth year-over-year. GAAP cash flow from operations was $900K in the second quarter of 2023; adjusted cash flow from operations was $5.9M. Ended the second quarter of 2023 with $127.8 million in cash, cash equivalents and marketable investment securities, which includes $40.0 million of borrowings under the new asset-based credit facility.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MYGN:
- Myriad Genetics Reports Second Quarter 2023 Financial Results and Reaffirms 2023 Revenue and Adjusted EPS Guidance; Generates the Fourth Consecutive Quarter of Double-Digit Year-Over-Year Testing Volume Growth
- MYGN Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Myriad Genetics to Release Second Quarter Financial Results on Aug. 3, 2023
- Myriad Genetics announces inclusion of breast density to MyRisk test
- Myriad Genetics Announces Inclusion of Breast Density to MyRisk® with RiskScore® Breast Cancer Risk Assessment